Similar articles

Abstract: ObjectiveThe present study used single-cell RNA sequencing (scRNA-seq) to characterize the cellular composition of ovarian carcinosarcoma (OCS) and identify its molecular characteristics.
MethodsscRNA-seq was performed in resected primary OCS for an in-depth analysis of tumor cells and the tumor microenvironment. Immunohistochemistry staining was used for validation. The scRNA-seq data of OCS were compared with those of high-grade serous ovarian carcinoma (HGSOC) tumors and other OCS tumors.
ResultsBoth malignant epithelial and malignant mesenchymal cells were observed in the OCS patient of this study. We identified four epithelial cell subclusters with different biological roles. Among them, epithelial subcluster 4 presented high levels of breast cancer type 1 susceptibility protein homolog (BRCA1) and DNA topoisomerase 2-α (TOP2A) expression and was related to drug resistance and cell cycle. We analyzed the interaction between epithelial and mesenchymal cells and found that fibroblast growth factor (FGF) and pleiotrophin (PTN) signalings were the main pathways contributing to communication between these cells. Moreover, we compared the malignant epithelial and mesenchymal cells of this OCS tumor with our previous published HGSOC scRNA-seq data and OCS data. All the epithelial subclusters in the OCS tumor could be found in the HGSOC samples. Notably, the mesenchymal subcluster C14 exhibited specific expression patterns in the OCS tumor, characterized by elevated expression of cytochrome P450 family 24 subfamily A member 1 (CYP24A1), collagen type XXIII α1 chain (COL23A1), cholecystokinin (CCK), bone morphogenetic protein 7 (BMP7), PTN, Wnt inhibitory factor 1 (WIF1), and insulin-like growth factor 2 (IGF2). Moreover, this subcluster showed distinct characteristics when compared with both another previously published OCS tumor and normal ovarian tissue.
ConclusionsThis study provides the single-cell transcriptomics signature of human OCS, which constitutes a new resource for elucidating OCS diversity.

单细胞转录组学揭示卵巢癌肉瘤的肿瘤特征

[1]AriyoshiK, KawauchiS, KakuT, et al., 2000. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology, 37(5):427-436.

[2]BoussiosS, KarathanasiA, Zakynthinakis-KyriakouN, et al., 2019. Ovarian carcinosarcoma: current developments and future perspectives. Crit Rev Oncol/Hematol, 134:46-55.

[3]CesconM, GattazzoF, ChenPW, et al., 2015. Collagen VI at a glance. J Cell Sci, 128(19):3525-3531.

[4]ChenPW, CesconM, BonaldoP, 2013. Collagen VI in cancer and its biological mechanisms. Trends Mol Med, 19(7):410-417.

[5]ChenX, ChenSW, YuDS, 2020. Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance. Metabolites, 10(7):289.

[6]CheungA, ShahS, ParkerJ, et al., 2022. Non-epithelial ovarian cancers: how much do we really know? Int J Environ Res Public Health, 19(3):1106.

[7]del CarmenMG, BirrerM, SchorgeJO, 2012. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol, 125(1):271-277.

[8]DingSN, ChenXS, ShenKW, 2020. Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun, 40(8):329-344.

[9]GaoCX, ShiJM, ZhangJX, et al., 2022. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(2):164-170.

[10]GeistlingerL, OhS, RamosM, et al., 2020. Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Res, 80(20):4335-4345.

[11]GeorgeEM, HerzogTJ, NeugutAI, et al., 2013. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol, 131(1):42-45.

[12]GhoseA, GullapalliSVN, ChohanN, et al., 2022. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes, 10(2):16.

[13]GotohO, SugiyamaY, TakazawaY, et al., 2019. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun, 10:4965.

[14]GuiYR, Aguilar-MahechaA, KrzemienU, et al., 2019. Metastatic breast carcinoma-associated fibroblasts have enhanced protumorigenic properties related to increased IGF2 expression. Clin Cancer Res, 25(23):7229-7242.

[15]HollisRL, CroyI, ChurchmanM, et al., 2022. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br J Cancer, 127(6):1034-1042.

[16]KanisMJ, KolevV, GetrajdmanJ, et al., 2016. Carcinosarcoma of the ovary: a single institution experience and review of the literature. Eur J Gynaecol Oncol, 37(1):75-79.

[17]KurmanRJ, ShihIM, 2011. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol, 42(7):918-931.

[18]LambMR, GertsenE, MiddlemasE, 2012. Carcinosarcoma of the ovary: case report and literature review. Tenn Med, 105(3):41-42.

[19]LeeHW, ChungW, LeeHO, et al., 2020. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med, 12:47.

[20]LiangLL, YuJ, LiJ, et al., 2021. Integration of scRNA-seq and bulk RNA-seq to analyse the heterogeneity of ovarian cancer immune cells and establish a molecular risk model. Front Oncol, 11:711020.

[21]LiuC, ZhangY, LiXH, et al., 2022. Ovarian cancer-specific dysregulated genes with prognostic significance: scRNA-seq with bulk RNA-seq data and experimental validation. Ann N Y Acad Sci, 1512(1):154-173.

[22]LiuFS, KohlerMF, MarksJR, et al., 1994. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol, 83(1):118-124.

[23]LuoQK, FuQ, ZhangX, et al., 2020. Application of single-cell RNA sequencing in pancreatic cancer and the endocrine pancreas. In: Yu BW, Zhang JQ, Zeng YM, et al. (Eds.), Single-cell Sequencing and Methylation. Springer, Singapore, p.143-152.

[24]MaXS, GuoJN, LiuKS, et al., 2020. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Mol Cancer, 19:147.

[25]MaynardA, McCoachCE, RotowJK, et al., 2020. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell, 182(5):1232-1251.e22.

[26]MenkeA, PhilippiC, VogelmannR, et al., 2001. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res, 61(8):3508-3517.

[27]NäyhäV, StenbäckF, 2008. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. APMIS, 116(2):107-117.

[28]Rauh-HainJA, GrowdonWB, RodriguezN, et al., 2011. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol, 121(3):477-481.

[29]Rauh-HainJA, DiverEJ, ClemmerJT, et al., 2013. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol, 131(1):46-51.

[30]RegnerMJ, WisniewskaK, Garcia-RecioS, et al., 2021. A multi-omic single-cell landscape of human gynecologic malignancies. Mol Cell, 81(23):4924-4941.e10.

[31]SiegelRL, MillerKD, JemalA, 2020. Cancer statistics, 2020. CA Cancer J Clin, 70(1):7-30.

[32]ThompsonSL, ComptonDA, 2011. Chromosomes and cancer cells. Chromosome Res, 19(3):433-444.

[33]TongDL, BoocockDJ, DhondalayGKR, et al., 2014. Artificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas. PLoS ONE, 9(7):e102483.

[34]XuJF, FangYF, ChenKL, et al., 2022. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res, 28(16):3590-3602.

[35]YangSX, PhamLK, LiaoCP, et al., 2008. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res, 68(1):198-205.

[36]ZhaoS, XiongW, XuK, 2020. MiR-663a, regulated by lncRNA GAS5, contributes to osteosarcoma development through targeting MYL9. Hum Exp Toxicol, 39(12):1607-1618.

[37]ZhuJ, WenH, JuXZ, et al., 2017. Clinical significance of programmed death ligand-1 and intra-tumoral CD8⁺ T lymphocytes in ovarian carcinosarcoma. PLoS ONE, 12(1):e0170879.

[38]Zibetti Dal MolinG, AbrahãoCM, ColemanRL, et al., 2018. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. Gynecol Oncol Res Pract, 5:6.

[39]ZorzouMP, MarkakiS, RodolakisA, et al., 2005. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol, 96(1):136-142.